NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-21-171 from the NIH Guide for Grants and Contracts. The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial a feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development.
Funding Opportunity PAR-21-172 from the NIH Guide for Grants and Contracts. The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.
Funding Opportunity PAR-21-170 from the NIH Guide for Grants and Contracts. The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. All applications submitted to this Funding Opportunity Announcement must propose basic science experimental studies involving humans, otherwise referred to in NOT-OD-18-212 as prospective basic science studies involving human participants, that fall within the NIH definition of a clinical trial and also meet the definition of basic research.
Funding Opportunity PAR-21-189 from the NIH Guide for Grants and Contracts. The goal of the Medical Scientist Training Program (MSTP) is to develop a diverse pool of highly trained physician-scientist leaders available to meet the needs of the Nations biomedical research agenda. Specifically, this funding opportunity announcement (FOA) provides support to eligible domestic institutions to develop and implement effective, evidence-based approaches to integrated dual-degree training leading to the award of both professional medical doctorate degrees and research doctorate degrees (Ph.D. or equivalent). With the dual qualification of rigorous scientific research and clinical practice, graduates will be equipped with the skills to develop research programs that accelerate the translation of research advances to the understanding, detection, treatment and prevention of human disease, and to lead the advancement of biomedical research. Areas of particular importance to NIGMS are the iterative optimization of MSTP training efficacy and efficiency, fostering the persistence of MSTP alumni in research careers, and enhancing the diversity of the physician-scientist workforce. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation.
Notice NOT-NS-21-037 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-OD-21-005 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this OBSSR R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. OBSSR and participating Institutes and Centers will support educational activities that develop cross-cutting methodologies and analytics that are needed to more rapidly advance behavioral and social sciences research (BSSR) and are not already well addressed by existing educational programs widely available to the research community. Methodological domains of focus include but are not limited to innovative data collection methodologies and analytic techniques, analysis and linking of big data, or needed but underused designs to advance research across the translational spectrum. Priority will be given to courses that address an important and cross-cutting educational need, that fill a gap in the field not already well addressed by other opportunities and that include a plan for increased reach and sustainability of the training both during and beyond the funding period. Over the period of support, it is expected that the course will be refined, improved, and sufficiently developed and implemented to extend beyond in-person attendance, and beyond the end of the project period (e.g. videos, slides, course materials).
Notice NOT-OD-21-072 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-073 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-122 from the NIH Guide for Grants and Contracts. This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.
Funding Opportunity PAR-21-123 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.
Funding Opportunity PAR-21-124 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.
Funding Opportunity PAR-21-190 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.
Notice NOT-NS-21-039 from the NIH Guide for Grants and Contracts
Notice NOT-AR-21-019 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-033 from the NIH Guide for Grants and Contracts
Notice NOT-MH-21-210 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MD-21-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to conduct innovative research supporting the development of a product, tool, technology, process or service for commercialization with the aim of eliminating disparities in socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minority populations or improving health in racial/ethnic minority populations.
Funding Opportunity RFA-MD-21-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more NIH-defined populations experiencing health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable.
Funding Opportunity PA-21-202 from the NIH Guide for Grants and Contracts. The Agency for Healthcare Research and Quality (AHRQ), in partnership with the Patient-Centered Outcomes Research Institute (PCORI), invites applications for funding to support innovative patient-centered outcomes research small pilot projects in Learning Health Systems (LHS) that evaluate the outcomes of embedded research and evaluate the processes by which embedded research can enhance impact, stakeholder engagement, and other health system-identified outcomes of interest.
Funding Opportunity RFA-NS-21-015 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. The result of the project should be to advance a hit or lead to the point where they can meet the entry criteria for RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) within the 5 years of the award, there is no opportunity for renewal of this award. Applications should propose a plan that will lead to the development of analgesics with a rigorous biological rationale and scientifically sound assays. If the data does not currently exist, the proposal must include a strong plan for developing data linking the putative therapeutic target(s) to the proposed pain indication and supporting the hypothesis that altering the target activity will produce desirable outcomes for the disease. This FOA is not specific for any one or group of pain conditions. Projects to develop therapeutics for acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, post stroke pain, myofascial pain, painful disorders of the orofacial region and other conditions will be considered.